StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Rating) in a research report sent to investors on Monday. The firm issued a hold rating on the biotechnology company’s stock.
Other equities research analysts have also issued research reports about the company. TheStreet raised Aptevo Therapeutics from a d rating to a c- rating in a research report on Friday, August 26th. Piper Sandler reduced their price target on Aptevo Therapeutics from $20.00 to $13.00 in a research report on Friday, August 12th.
Aptevo Therapeutics Trading Up 1.4 %
APVO stock opened at $2.97 on Monday. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.12. The business’s 50-day moving average is $3.03 and its two-hundred day moving average is $3.71. Aptevo Therapeutics has a 1 year low of $2.67 and a 1 year high of $15.33.
Institutional Investors Weigh In On Aptevo Therapeutics
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome.
- Get a free copy of the StockNews.com research report on Aptevo Therapeutics (APVO)
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.